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Background: Isolated limb perfusion (ILP) with tumor necrosis factor alpha (TNF-a) and
melphalan, followed by delayed surgical resection and adjuvant external-beam radiotherapy is
a limb salvage treatment strategy for locally advanced soft tissue sarcomas. The long-term
vascular side effects of this combined procedure were evaluated.
Methods: Thirty-two patients were treated for a locally advanced sarcoma of the upper
(n = 5) or lower limb (n = 27). All patients underwent a noninvasive vascular work-up.
Results: Five patients underwent a leg amputation, in two cases due to critical leg ischemia
10 years after ILP. With a median follow-up of 88 (range, 17–159) months, none of the
patients with a salvaged lower leg (n = 22) experienced peripheral arterial occlusive disease.
Ankle-brachial index (ABI) measurements in the involved leg (median, 1.02; range, .50–1.20)
showed a significant decrease compared with the contralateral leg (median, 1.09; range, .91–
1.36, P = .001). Pulsatility index (PI) was decreased in the treated leg in 17 of 22 patients at
the femoral level (median, 6.30; range, 2.1–23.9 vs. median, 7.35; range, 4.8–21.9; P = .011)
and in 19 of 20 patients at popliteal level (median, 8.35; range, 0–21.4 vs. median, 10.95; range,
8.0–32.6; P < .0005). In patients with follow-up of >5 years, there was more often a decrease
in ABI (P = .024) and PI at femoral level (P = .011).
Conclusions: ILP followed by resection and external-beam radiotherapy can lead to major
late vascular morbidity that requires amputation. Objective measurements show a time-related
decrease of ABI and femoral PI in the treated extremity.
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Optimum treatment strategies for locally advanced
soft tissue sarcoma (STS) of the extremities have
evolved considerably over the past 25 to 30 years. In
1982, Rosenberg et al.
1 showed that amputations or
exarticulations of the affected limb do not result in
higher survival rates. This made preservation of the
extremity and good limb function all the more
important.
2,3 An established limb salvage strategy is
to perform a hyperthermic isolated limb perfusion
(ILP) with tumor necrosis factor alpha (TNF-a) and
melphalan, followed by delayed tumor resection and,
in case of marginal or nonradical resection, by
adjuvant external-beam radiotherapy (EBRT).
4,5 Al-
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2105though ILP, in which high doses of chemotherapy are
regionally delivered, is a technically demanding
operative procedure, amputation necessitated by
peri- or postoperative surgical complications occurs
in <1% of cases.
4 On the other hand, patients
undergoing an intentionally limb-saving treatment
with ILP still have a short- or long-term risk up to
40% of loss of the affected limb due to massive
necrosis of the tumor and overlying skin resulting in a
soft tissue deﬁcit, late local recurrence, or critical leg
ischemia.
5
In ILP, cytotoxic agents are used, which cause a
local toxic eﬀect in the perfused extremity. After
investigation of several perfusion agents for STS, the
two-drug regimen of TNF-a and melphalan turned
out to be highly eﬀective.
4 The pathological tumor
microvascularization is the primary target for TNF-
a, resulting in coagulative and hemorrhagic necrosis
of the tumors.
6 Olieman et al.
7 demonstrated by
angiography ﬁndings of speciﬁc destruction of tumor
vessels after perfusion with TNF-a, leaving the nor-
mal vasculature unchanged. The surgical procedure
of ILP, however, exposes the cannulated blood ves-
sels to intravascular manipulation, by means of ar-
teriotomy, venotomy, and the insertion of catheters.
Consequently, a 1% to 10% risk of developing acute
vascular complications, such as thrombosis at the
arteriotomy site and deep-vein thrombosis (DVT),
has been described in the literature.
8–10 Moreover,
chemotherapy and atherosclerosis risk factors could
have a synergistic role on the development of arterial
stenosis.
11 Adjuvant EBRT leads to a high incidence
of early and late morbidity. Long-term vascular side
effects, in particular arterial stenosis, can be induced
by radiotherapy.
12–14
Because little is known with respect to the late
vascular morbidity of the combined procedure of ILP
and EBRT, a retrospective study was conducted to
evaluate the long-term locoregional vascular side ef-
fects of ILP, followed by delayed surgical resection
and adjuvant high-dose EBRT.
PATIENTS AND METHODS
From 1991 to 2003, a total of 73 patients with a
median age of 54 (range, 14–80) years and with lo-
cally advanced STS underwent 77 perfusions with a
combination of TNF-a and melphalan, with
(n = 19) or without (n = 58) interferon gamma at
the Division of Surgical Oncology of the University
Medical Center Groningen, University of Groningen.
The perfusion technique has been previously exten-
sively described.
15,16 Perfusion was followed by de-
layed local resection of the tumor remnant, and in
cases of marginal or microscopically positive resec-
tion margins, high-dose postoperative EBRT was
considered.
In 2005, 39 patients were still alive and in follow-
up. Information about their past and current onco-
logical and vascular status was obtained from the
follow-up notes in the medical records. Seven patients
were unable to participate in the study because of
severe or advanced morbidity or comorbidity (n = 2)
or because of nonmedical reasons (n = 5). Conse-
quently, 32 patients, 14 men (44%) and 18 women
(56%), with a median age of 47 (range, 14–71) years,
were included (response rate, 82%). They completed a
vascular checklist that asked questions about their
medical vascular history, and they were screened for
risk factors of vascular disease, such as smoking,
hypertension, and diabetes. A blood sample was
drawn to determine the cholesterol spectrum, which
was used as an indicator of risk for atherosclerosis.
All patients underwent a noninvasive arterial and
venous vascular work-up that comprised duplex
ultrasonography and vascular pressure measure-
ments. The ankle-brachial index (ABI) and pulsatility
index (PI), which are indications of vascular blood
flow velocity, were measured to indicate the arterial
status of the limb. For evaluation of veins, ultraso-
nography was performed to detect DVT and insuffi-
ciency. All investigations were performed by the same
examiner (J.L.).
Five patients had a STS of the upper extremity
(16%) treated with axillary perfusion. The remain-
ing 27 patients had a STS located in the lower limb
(84%) and were treated with iliac (n = 13, 41%),
femoral (n = 5, 16%), or popliteal (n = 9, 28%)
perfusion. There were 27 primary STS and 5
recurrent STS. Twenty-four patients (75%) received
adjuvant 60 to 70 Gy EBRT in fractions of 2 Gy.
Adjuvant systemic chemotherapy was provided to
seven patients. Deﬁnite histopathological classiﬁca-
tion of tumor (one embryonal rhabdomyosarcoma
and one extraossal osteosarcoma) was the reason in
two patients; three patients were treated with che-
motherapy because they participated in an Euro-
pean Organization for the Research and Treatment
of Cancer trial (EORTC 62931). Two patients re-
ceived chemotherapy in a palliative setting for dis-
tant metastasis. All patients were treated after
informed consent was obtained according to insti-
tutional guidelines. Twelve diﬀerent histological
types of STS were distinguished. The pathological
grade of the tumor was scored following the criteria
M. L. HOVEN-GONDRIE ET AL. 2106
Ann. Surg. Oncol. Vol. 14, No. 7, 2007of Coindre et al.,
17 and the stage of the tumor was
assigned according to the American Joint Com-
mittee on Cancer.
18 Patient and tumor characteris-
tics are summarized in Table 1.
The results were statistically analyzed by the Wil-
coxon rank test and the Mann-Whitney U-test. Val-
ues of P £ .05 were considered signiﬁcant. SPSS
12.0.1 for Windows statistical software was used
(SPSS, Chicago, IL).
RESULTS
Before ILP, none of the patients had a history of
cerebrovascular insuﬃciency, coronary artery dis-
ease, peripheral arterial occlusive disease, or any
other vascular disease. Risk factors for cardiovascu-
lar disease, hypertension, diabetes, smoking, obesity,
hypercholesterolemia, and familiar arterial occlusive
disease were analyzed (Table 2).
Two patients underwent vascular reconstruction
after en-bloc tumor resection with the artery. One
patient underwent a reconstruction of the femoral
artery with an infragenual femoral-popliteal bypass,
and the second patient underwent a popliteal artery
reconstruction with an autologous vein graft. A DVT
in the lower leg was diagnosed in the postoperative
period in three patients (7.7%).
Nine (23%) of the 39 alive patients underwent a
lower limb amputation at diﬀerent levels after ILP
with or without EBRT. No amputations of the upper
extremity were performed. In two patients with
microscopically involved resection margins, an
amputation of the aﬀected limb was indicated be-
cause adjuvant radiotherapy was contraindicated.
One patient underwent amputation due to tumor
recurrence 18 months after ILP and EBRT. Ampu-
tation was performed for critical leg ischemia due to
atherosclerosis in two patients at 110 and 125 months
after ILP and EBRT. Because of severe obstruction
of the crural vessels, reconstructive therapy was not
suitable.
The other four amputations were performed for
extensive postperfusion necrosis of the involved
tumor site (three patients at 0, 8, and 12 months
after ILP with or without EBRT) and arterial
occlusion without any vascular reconstructive pos-
sibilities (one patient 15 months after ILP and
EBRT).5[A1] Figure 1 illustrates treatment, out-
come, and reasons for amputation. Five of the 32
patients included in this study underwent amputa-
tion and could therefore only partially undergo
vascular follow-up.
Arterial Vascular Disease
With a median follow-up of 88 (range, 17–159)
months, no patient experienced peripheral arterial
occlusive disease. With duplex ultrasonography,
however, two patients showed a complete arterial
occlusion at the level of cannulation (6%). One of
them underwent an iliac perfusion and EBRT be-
cause of a STS of the lower leg in 1993. After 10
years, she had signs of critical leg ischemia, which
required a transfemoral amputation. She is now free
of pain and can walk with a well-functioning proth-
esis. The other patient showed an axillary occlusion
10 years after an axillary perfusion, followed by
resection and EBRT at the forearm. She did not have
any symptoms of arterial occlusive disease, and her
arm functions normally. Duplex ultrasonography
showed good collateral flow. Two other patients (6%)
showed an arterial stenosis at cannulation level at 22
and 30 months after axillary perfusions, followed by
EBRT at the upper arm and axilla in one and sys-
temic chemotherapy in both patients. They had nor-
mal arm function without any signs of ischemia.
The arteries at resection level were also evaluated.
One patient with a fossa poplitea STS had complete
occlusion of the superﬁcial femoral artery 6 years after
ILP and EBRT, with open arteries below knee level. A
femoral-popliteal bypass was considered but was not
performedbecauseoftheabsenceofanysymptoms.At
the time of evaluation,the ABI was .50; the patient did
nothaveanycomplaintsbesidescompressionulcerson
his feet,which responded well to conservative therapy.
Thepatientwhoneededanautologousveingraftofthe
popliteal artery has a stenosis at this level without
clinical signs of arterial occlusive disease.
Twenty-two of the total 32 patients included
underwent ABI measurements; 22 had their PI
determined at the femoral level and 20 at the popliteal
level. Five patients were excluded because of ampu-
tation of the limb; another ﬁve were excluded because
of a STS located in the upper limb. Of the remaining
22 patients, 18 received postoperative EBRT for the
above-described indications.
In 21 of 22 patients, the ABI (normal, ‡1.00) in the
treated leg was .91 or more. As mentioned above, one
patient had an ABI of .50 without any complaints.
ABI measurements in the involved leg (median, 1.02;
range, .50–1.20) showed a significant decrease com-
pared with the contralateral leg (median, 1.09; range,
.91–1.36; P = .001). Seven patients showed a de-
creased femoral PI (normal range, 5–10). Six of them
underwent an iliac perfusion (86%). Popliteal PI
(normal range, 6–12) was decreased in six patients.
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four of these patients (67%). When compared with
the contralateral leg, PI was lower in the treated leg in
17 of 22 patients at femoral level (median, 6.30;
range, 2.1–23.9 vs. median, 7.35; range, 4.8–21.9;
P = .011) and in 19 of 20 patients at popliteal level
(median, 8.35; range, 0–21.4, vs. median, 1.95; range,
8.0–32.6; P < .0005) (Table 3). There were no dif-
ferences in objective vascular side effects between
men and women, between patients who did or did not
undergo EBRT, or between patients <50 years old
versus older patients (Table 4). In patients with a
follow-up period of >5 years, there was more often a
decrease in ABI, compared with patients with shorter
follow-up (13 of 14 patients vs. 4 of 8 patients,
P = .024). With a longer follow-up period, there was
also more often a decrease in PI at the femoral level
(13 of 14 patients vs. 3 of 7 patients, P = .024), but
not at the popliteal level (12 of 12 patients vs. 7 of 8
patients, P = .221) (Table 5). No patient required
vascular intervention during follow-up.
Venous Vascular Disease
Many patients had some symptoms of venous
insuﬃciency, such as lower limb pain, feelings of
TABLE 1. Characteristics of patients
Age (y) Sex Disease Localization Histology Grade
AJCC
stage Level EBRT Amputation
Follow-up
(mo)
18 F Primary Upper leg Embryonal rhabdomyosarcoma 3 3 Iliac N N 159
44 F Recurrent Popliteal fossa Myxoid liposarcoma 1 1 Iliac Y N 152
43 M Primary Upper leg Synovial sarcoma 3 3 Iliac Y N 151
18 M Primary Lower leg Myxoid chondrosarcoma 2 3 Popliteal Y Y 149
48 F Primary Upper leg Well differentiated liposarcoma 1 1 Iliac Y N 143
56 F Primary Proximal tibia PNET 3 3 Iliac Y Y 137
50 F Recurrent Foot PUS 3 3 Popliteal N N 135
25 F Primary Popliteal fossa Synovial sarcoma 2 3 Popliteal Y N 132
44 M Primary Upper leg Myxoid liposarcoma 1 1 Iliac Y N 131
24 M Recurrent Lower leg Synovial sarcoma 2 3 Popliteal Y N 129
37 F Primary Elbow MPNST 2 3 Axillary Y N 121
48 M Primary Popliteal fossa Myxoid liposarcoma 2 3 Iliac Y N 111
63 F Recurrent Lower leg PUS 2 3 Popliteal N Y 107
37 M Primary Upper leg Myxoid liposarcoma 1 1 Iliac Y N 105
58 M Primary Upper leg PUS 2 3 Iliac Y N 98
71 F Primary Upper leg Leiomyosarcoma 1 1 Femoral N N 94
45 F Primary Upper leg PUS 3 3 Iliac N N 82
56 F Primary Lower leg PUS 3 3 Popliteal Y N 61
63 M Primary Popliteal fossa Myxoid chondrosarcoma 3 Femoral Y N 50
37 F Primary Knee Leiomyosarcoma 1 1 Femoral Y N 36
28 M Primary Popliteal fossa Synovial sarcoma 2 3 Femoral Y N 36
57 F Primary Upper leg PUS 3 3 Femoral Y N 35
42 F Primary Knee Synovial sarcoma 2 3 Iliac Y Y 32
47 F Primary Arm PUS 3 3 Axillary Y N 30
58 F Primary Lower leg PUS 3 3 Popliteal Y N 26
27 M Primary Arm Epithelioid sarcoma 3 4 Axillary Y N 26
71 M Recurrent Arm Myxoid ﬁbrosarcoma 1 1 Axillary N N 24
56 F Primary Arm Extraosseal osteosarcoma 3 3 Axillary N N 22
14 M Primary Lower leg PUS 3 3 Popliteal Y N 20
65 F Primary Foot Synovial sarcoma 2 3 Popliteal N Y 18
63 M Primary Upper leg Synovial sarcoma 3 3 Iliac Y N 17
71 M Primary Upper leg Rhabdomyosarcoma 3 3 Iliac Y N 17
AJCC, American Joint Committee on Cancer; EBRT, external-beam radiotherapy; PNET, primitive neuroectodermal tumor; PUS,
pleomorphic undiﬀerentiated sarcoma; MPNST, malignant peripheral nerve sheath tumor.
TABLE 2. Risk factors for atherosclerosis
Risk factor n %
Dutch population
(%)
Hypertension 10 31 9.9
a,b
Diabetes mellitus 4 13 3.1
b
Smoking 29.6
b
Smokers 9 28
Former smokers 10 31
BMI
BMI >25.0 17 53 46.5
b
BMI >30.0 4 13 10.9
b
Hypercholesterolemia
(total cholesterol >6.5)
61 91 4
c
Familiar cardiovascular disease 14 44 NA
BMI, body mass index; NA, not available.
a Range, 5% to 45%.
b From http://www.cbs.nl/.
c From http://www.hartstichting.nl/.
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and edema. One patient (3%) wore compression
stockings because of superﬁcial vena saphena magna
insuﬃciency, and one patient (3%) had unilateral
superﬁcial varicosis in the treated leg. Another three
patients (9%) showed uni- or bilateral deep insuﬃ-
cient venous vasculature by duplex ultrasonography,
which in all cases was located at the level of resection.
One DVT (3%) and one partial venous obstruction
(3%) were found, both at the resection level. Venous
vascular obstruction was not seen at the level of
cannulation.
DISCUSSION
ILP with TNF-a and melphalan, with or without
adjuvant EBRT, has become an approved treatment
strategy for locally advanced STS of the extremities
after the publication of the results of an European
multicenter trial performed in the 1990s.
4 Because
our center was one of the ﬁrst to use this treatment
modality, we now have had more than 10 years
experience of ILP used to treat STS. This gives us the
opportunity to evaluate the long-term treatment-re-
lated morbidity. Critical leg ischemia approximately
10 years after ILP, necessitating amputation in two
patients, led to an interest of analyzing the vascular
complications of ILP with or without EBRT.
5
Despite a complete destruction of tumor vascula-
ture, ILP does not seem to have any eﬀect on the
macrovasculature of the perfused limb.
7,19,20 How-
ever, because atherosclerosis risk factors and che-
motherapy could play a synergistic role in the
progression of arterial stenosis, patients who already
have severe atherosclerotic disease are less suitable
for ILP.
11,19,20
In our study, many patients had one or more risk
factors for atherosclerosis. In the study population,
there seemed to be more patients with diabetes or
hypercholesterolemia than in the standard Dutch
population. The smoking rate is similar (28% vs.
30%); however, another 31% used to smoke (Ta-
ble 2).
Acute vascular complications after ILP have been
described in the literature. Deep-vein thrombosis
(DVT) occurs in 1.7% to 10% of cases in the imme-
diate postoperative period.
10 In our studies, three
patients (7.7%) had a successfully treated DVT after
ILP. DVT seems to be extremely difﬁcult to diagnose
because the postoperative effects of ILP itself—a
warm, swollen edematous limb—mask the classical
symptoms. To prevent this undesired complication,
anticoagulant therapy is recommended. Thrombosis
at the arteriotomy site has also been mentioned in
earlier studies. It was not encountered in this study
but should be treated by prompt trombectomy.
9,21 In
case of repeated ILP in the same limb, perfusion
through more proximal arterial and venous sites is
recommended because ﬁbrosis at the previous oper-
TABLE 3. Results of ankle-brachial index (ABI) and
pulsatility index (PI) measurements in lower extremities of
22 patients
Index
Treated extremity,
median (range)
Contralateral extremity,
median (range) P value
ABI 1.02 (.50–1.20) 1.090 (.91–1.36) .001
PI femoral 6.30 (2.1–23.9) 7.35 (4.8–21.9) .011
PI popliteal 8.35 (.0–21.4) 10.95 (8.0–32.6) <.0005
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FIG. 1. Flow chart illustrating treatment, outcome, and reasons for amputation. EBRT, external-beam radiotherapy; AMP, amputation; NI,
not included in this study.
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the same level. All patients in this study underwent
only one ILP.
Long-term eﬀects after ILP are mainly functional
and consist of edema, stiﬀness, functional impair-
ment, and muscle atrophy.
21–23 Late vascular mor-
bidity after ILP without EBRT has not been
previously mentioned in other studies. In our study,
one partial arterial occlusion (3%) was found. In
contrast, long-term effects of EBRT have extensively
been described in the literature. In a study of Butler
et al.,
12 three types of vascular damage have been
described. At ﬁrst, thrombosis occurs within 5 years
after EBRT; a second ﬁbrotic occlusion is seen within
10 years; and ﬁnally, a predisposition to the devel-
opment of atheroma together with periarterial ﬁbro-
sis is associated with a latent interval of 20 or more
years. Rijbroek et al.
24 mention claudication after a
latent period. This is masked by the other effects such
as pain, functional impairment, and edema. Accord-
ing to Kalman et al.,
13 long-term vascular side effects
of EBRT resemble the natural process of athero-
sclerosis, which is a combination of direct damage,
periarterial ﬁbrosis, and occlusion of vasa vasorum.
The EBRT accelerates this process, sometimes 10 to
27 years after treatment. Little is known about the
combined effects of ILP and EBRT. Vrouenraets
et al.
22 described one brachial arterial occlusion, but
this was only 4 months after treatment. Olieman
et al.
16 described the occurrence of necrosis after ILP
but did not ﬁnd any increased tumor-related mor-
bidity after ILP followed by EBRT. In another series,
ILP was performed after EBRT, but it did not lead to
more local toxicity or complications.
25
In our study, amputation was performed in nine
patients (23%). This is higher than the 9% to 21%
described in the literature.
4,26,27 However, amputa-
tions due to long-term complications like critical leg
ischemia, which was performed in two patients
(5.1%), have not been described in other studies.
Furthermore, three complete (9%) and one partial
(3%) arterial occlusion were found after the combined
procedure.
Fortunately, these patients did not have invalidat-
ing symptoms of arterial occlusive disease. In most
cases, vascular pressure measurements and duplex
ultrasonographic evaluation showed statistically
lower values compared with the contralateral
extremity, but these were still within the normal
range. This could explain the absence of symptoms.
The PI value normally increases progressively from
aorta to ankle. A decrease in PI indicates stenosis in a
more proximal vascular segment.
28 In our study, six
of seven patients with an abnormal femoral PI
underwent iliac perfusion. This implies a vascular
reaction at the level of cannulation. Furthermore,
seven patients showed a decrease in popliteal PI
compared with the femoral PI, which implies that
vascular damage is present at a more proximal (i.e.,
cannulation or resection) level. However, with the
present data, it is not possible to support this thesis
because of the relatively small study population, and
the absence of symptoms and other abnormal out-
comes of the vascular work-up.
It is important to realize that blood vessels lose
their elasticity with the years and are subject to the
normal process of atherosclerosis. Furthermore,
unilateral peripheral arterial occlusive disease is
common. However, the fact that lower rates of ABI
and PI were found in the treated leg in almost all
TABLE 4. P values of differences between subgroups in decrease of ankle-brachial index (ABI) and pulsatility index (PI) for
22 patients
Characteristic
Sex
Follow-up after
EBRT Age
F M Yes No >5 y <5 y <50 y >50 y
No. of patients 11 11 18 4 14 8 13 9
ABI .619 .241 .024 .963 – – – –
PI femoral decrease .619 .907 .024 .963 – – – –
PI popliteal decrease .269 .937 .221 .414 – – – –
EBRT, external-beam radiotherapy.
TABLE 5. Differences in decreases in measurements
according to length of follow-up
Decrease in
perfused leg
Follow-up, n (%)
P value
>5 y
(n = 14)
<5 y
(n = 8)
ABI 13 (93%) 4 (50%) .024
PI femoral 13 (93%) 4 (50%) .024
PI popliteal 12 (100%)
a 7 (88%) .221
ABI, ankle-brachial index; PI, pulsatility index.
a n = 12; data for two patients were not available.
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between younger and older patients makes the
assumption of treatment-induced diﬀerences plausi-
ble.
Because only four patients with a lower leg STS
were not treated with adjuvant EBRT, there are still
no clinically relevant data about the late vascular
damage of the single procedure of ILP. Thijssens
et al.
29 showed that adjuvant EBRT seems beneﬁcial
in all patients, so it might be impossible to evaluate
the sole effects of ILP on the vascular system in the
future.
Major late vascular complications after the com-
bined procedure, like critical leg ischemia necessitat-
ing amputation, were found in two patients in this
study. One patient had no risk factors for peripheral
arterial occlusive disease besides smoking. He had
had intermittent claudication 8 years after ILP and
EBRT, and a normal ABI of 1.09. His condition did
not improve after 2 years of conservative therapy and
reconstruction was impossible, so he underwent an
amputation 125 months after the initial limb salvage
treatment strategy. The second patient, who had
diabetes mellitus and familial cardiovascular disease,
experienced no complications the ﬁrst few years after
ILP and EBRT. After 6 years, she experienced a
pathological proximal tibia fracture due to radiation-
induced osteonecrosis in the previous surgically
treated area and needed to wear a brace. She lived for
3 years with a disabling function impairment of the
knee and then developed signs of critical leg ischemia.
An upper leg amputation was performed 110 months
after the initial treatment. She now walks with a well-
functioning prothesis.
The importance of leg preservation has been
mentioned before. Even though most patients still are
satisﬁed with the initial limb-saving treatment that
they underwent, amputations due to major late
complications with severe morbidity make the ratio-
nale of limb salvage worth reconsidering.
Recently, one patient was successfully treated with
thrombectomy for an acute popliteal artery occlu-
sion. This patient, who underwent an ILP at femoral
level followed by EBRT for a STS in the fossa po-
plitea 5 years before, had no complaints of peripheral
arterial occlusive disease during his vascular work-up
for this study 10 months earlier. ABI (1.03) and
femoral PI (6.3) were normal; popliteal PI was low
(5.3). With duplex ultrasonography, some athero-
sclerosis in the femoropopliteal section was seen. This
patient has diabetes and hypertension, is obese (body
mass index >30), and was a former smoker, so he
was especially at risk for developing atherosclerosis.
This study shows that despite the importance of
preventing major late vascular complications after
the combined procedure of ILP and EBRT, a routine
noninvasive vascular work-up does not seem to add
value to normal follow-up. It is more important to
realize that patients after the limb salvage treatment
strategy of ILP, followed by delayed tumor resection
and EBRT, are at risk for late vascular complica-
tions. This risk is substantially raised when personal
risk factors such as smoking, diabetes, hypertension,
obesity, and hypercholesterolemia are present. Be-
cause symptoms of vascular complications can be
masked by the normal eﬀects of the treatment itself,
the possibility of vascular morbidity should be con-
sidered if the patient has any complaint. Further-
more, all patients must be convinced of the
importance of reducing their additional personal risk
factors for atherosclerosis.
In conclusion, objective measurements show a
time-related decrease (>5 years follow-up) of ABI
and femoral PI in the treated leg, usually without
subjective complaints. ILP followed by delayed
resection and EBRT for a locally advanced STS can
lead to major late vascular morbidity that requires
amputation.
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